In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), asciminib; and 11 (13.8%), both medications. 1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic ...